Flag Ship Acquisition (NASDAQ:ETHZ) Stock Price Down 11.4% - Time to Sell?

Key Points

• Flag Ship Acquisition Corp. saw its stock price decline by 11.4% during mid-day trading, reaching a low of $14.74 and last at $15.17.
• Analysts have issued a "strong sell" rating, with an average rating of "Sell" as the company faces a negative outlook.
• The company has a market capitalization of $2.72 billion and a price-to-earnings ratio of -1.10, indicating poor earnings performance.

Flag Ship Acquisition Corp. (NASDAQ:ETHZ - Get Free Report)'s stock price was down 11.4% during mid-day trading on Tuesday . The company traded as low as $14.74 and last traded at $15.17. Approximately 639,730 shares changed hands during mid-day trading, an increase of 17% from the average daily volume of 548,856 shares. The stock had previously closed at $17.12.

Analysts Set New Price Targets

A number of analysts recently issued reports on ETHZ shares. Wall Street Zen lowered shares of Flag Ship Acquisition to a "strong sell" rating in a research note on Saturday, August 30th. Weiss Ratings restated a "sell (d-)" rating on shares of Flag Ship Acquisition in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of "Sell".

Flag Ship Acquisition Stock Performance

The company has a market cap of $2.72 billion, a price-to-earnings ratio of -1.10 and a beta of 0.38.

Flag Ship Acquisition Company Profile

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.